i for more information. ) based on this analysis , we identified the label names of drugs that had extraordinary price increases by their ndc - 9 code . awp records in red book are reported by the drug manufacturer and published in red book . in some cases , when drug manufacturers do not report awp , red book calculates awp from other drug pricing benchmarks provided by drug manufacturers . gao did not audit the drug pricing information reported to red book by drug manufacturers nor the calculations performed by red book to fill nonreported awp data . some of the drugs on this list were repackaged , or nonrepackaged , while other drugs were both repackaged and nonrepackaged . in a few cases , drugs were removed from the list because changes in the recorded package size led to errors in the calculated change in unit prices . see table 6 below for the label names of brand - name prescription drugs that had an extraordinary price increase between 2000 and 2008 . to gain an understanding of the market dynamics leading to extraordinary price increases for brand - name drugs , we developed case studies of six brand - name drugs identified from our analysis of red book data . selection for inclusion as a case study was based on several factors including price , the level of the percentage increase , whether the drug had more than one extraordinary price increase between 2000 and 2008 , availability of the drug from multiple sources , and the permanence of the price increase . see table 8 for characteristics of the drugs selected for the case studies . john e. dicken at ( 202 ) 512-7114 or dickenj@gao.gov . in addition to the contact named above , martin t. gahart , assistant director ; n. rotimi adebonojo ; rashmi agarwal ; george bogart ; kristin helfer koester ; martha kelly ; yesook merrill ; giao n. nguyen ; daniel ries ; and timothy walker made major contributions to this report . medicaid outpatient prescription drugs: second quarter 2008 federal upper limits for reimbursement compared with average retail pharmacy acquisition costs . gao - 10-118r . washington , d.c.: november 30 , 2009 . prescription drugs: overview of approaches to control prescription drug spending in federal programs . gao - 09-819t . washington , d.c.: june 24 , 2009 . medicare part d prescription drug coverage: federal oversight of reported price concessions data . gao - 08-1074r . washington , d.c.: september 30 , 2008 . prescription drugs: trends in usual and customary prices for drugs frequently used by medicare and non - medicare health insurance enrollees . gao - 07-1201r . washington , d.c.: september 7 , 2007 . prescription drugs: oversight of drug pricing in federal programs . gao - 07-481t . washington , d.c.: february 9 , 2007 . prescription drugs: an overview of approaches to negotiate drug prices used by other countries and u.s . private payers and federal programs . gao - 07-358t . washington , d.c.: january 11 , 2007 . medicaid outpatient prescription drugs: estimated 2007 federal upper limits for reimbursement compared with retail pharmacy acquisition costs . gao - 07-239r . washington , d.c.: december 22 , 2006 .